British Journal of Cancer · 2013 · 175 citations · 40 references
MedicineOncologyPharmacologyChemotherapyPharmacogeneticsPharmacogenomicsCancer PharmacogenomicsChemotherapy PharmacogenomicsDrug ToxicityPharmacogenetic TestingToxicity GradingToxicity Risk Assessment5-Fluorouracil PharmacogeneticsCapecitabine-based TherapyChemotherapy-related ToxicityDpyd Fluoropyrimidine ToxicityDpyd GenotypeLogistic RegressionPatient Demographic VariablesPredictors Of Severe Toxicity
BACKGROUND: Fluoropyrimidine drugs are extensively used for the treatment of solid cancers. However, adverse drug reactions are a major clinical problem, often necessitating treatment discontinuation. The aim of this study was to identify pharmacogenetic markers predicting fluoropyrimidine toxicity. METHODS: Toxicity in the first four cycles of 5-fluorouracil or capecitabine-based chemotherapy were recorded for a series of 430 patients. The association between demographic variables, DPYD, DPYS, TYMS, MTHFR, CDA genotypes, and toxicity were analysed using logistic regression models. RESULTS: Four DPYD sequence variants (c.1905+1G>A, c.2846A>T, c.1601G>A and c.1679T>G) were found in 6% of the cohort and were significantly associated with grade 3-4 toxicity (P<0.0001). The TYMS 3'-untranslated region del/del genotype substantially increased the risk of severe toxicity (P=0.0123, odds ratio (OR)=3.08, 95% confidence interval (CI): 1.38-6.87). For patients treated with capecitabine, a MTHFR c.1298CC homozygous variant genotype predicted hand-foot syndrome (P=4.1 × 10⁻⁶, OR=9.99, 95% CI: 3.84-27.8). The linked CDA c.-92A>G and CDA c.-451C>T variants predicted grade 2-4 diarrhoea (P=0.0055, OR=2.3, 95% CI: 1.3-4.2 and P=0.0082, OR=2.3, 95% CI: 1.3-4.2, respectively). CONCLUSION: We have identified a panel of clinically useful pharmacogenetic markers predicting toxicity to fluoropyrimidine therapy. Dose reduction should be considered in patients carrying these sequence variants.
40
Nobuyuki Horie, Hideo Aiba, Katsuhiko Oguro et al. · Cell Structure and Function · 1995 · 550 citations · Full text
Matthias Schwab, Ulrich M. Zanger, Claudia Marx et al. · Journal of Clinical Oncology · 2008 · 394 citations · Full text
Michael V Mandola, Jan Stoehlmacher, Susan Muller‐Weeks et al. · PubMed · 2003 · 363 citations